Conventional Transarterial Chemo embolization Using Streptozocin in Patients with Unresectable Neuroendocrine Liver Metastases

Background: The purpose of this study was to evaluate the clinical, biological and radiological responses to, tolerability of, conventional transarterial chemoembolization (cTACE) using streptozocin for unresectable neuroendocrine liver metastases. Patients Methods: A total 52 patients with predominant disease were treated cTACE an emulsion streptozocin, Lipiodol embolization particles. sequential approach favored in high tumor burden. Clinical, evaluated carcinoid symptoms, biomarkers mRecist criteria, respectively. Results: 127 procedures performed a 65% patients. All received Lipiodol. Carcinoid syndrome improved 69% after treatment (p = 0.01). Post-embolization reported 78% At end all cTACE, objective response non-progressive 32% 70%, Progression-free survival 18.3 ± 13.3 months (median 14.9) median overall (OS) from start 74 months. OS at 1 year, 2 years, 3 years 5 91% (IC 84–99%), 84% (CI 72–95%), 53–84%) 63% (C 46–81%), Conclusions: is effective well-tolerated palliative option metastases, associated prolonged delayed time progression.